Sage Mountain Advisors LLC Trims Stock Holdings in AstraZeneca PLC $AZN

Sage Mountain Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN) by 7.9% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,122 shares of the company’s stock after selling 356 shares during the period. Sage Mountain Advisors LLC’s holdings in AstraZeneca were worth $288,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of AZN. Brighton Jones LLC lifted its holdings in AstraZeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after buying an additional 2,789 shares during the last quarter. GAMMA Investing LLC raised its position in shares of AstraZeneca by 43.3% during the 1st quarter. GAMMA Investing LLC now owns 7,878 shares of the company’s stock worth $579,000 after purchasing an additional 2,380 shares during the period. Spire Wealth Management raised its position in shares of AstraZeneca by 10.6% during the 1st quarter. Spire Wealth Management now owns 7,065 shares of the company’s stock worth $519,000 after purchasing an additional 679 shares during the period. Sequoia Financial Advisors LLC raised its position in shares of AstraZeneca by 23.6% during the 1st quarter. Sequoia Financial Advisors LLC now owns 35,711 shares of the company’s stock worth $2,625,000 after purchasing an additional 6,817 shares during the period. Finally, Diversified Trust Co raised its position in shares of AstraZeneca by 7.8% during the 1st quarter. Diversified Trust Co now owns 6,069 shares of the company’s stock worth $446,000 after purchasing an additional 439 shares during the period. Institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a research report on Friday. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, October 16th. Finally, Berenberg Bank set a $97.00 target price on AstraZeneca in a research report on Wednesday, July 9th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $86.00.

AstraZeneca Stock Performance

Shares of NASDAQ AZN opened at $83.29 on Monday. The stock has a fifty day moving average price of $80.87 and a two-hundred day moving average price of $74.46. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86. The firm has a market cap of $258.32 billion, a P/E ratio of 31.31, a PEG ratio of 1.54 and a beta of 0.36. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $86.57.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.09. The firm had revenue of $14.46 billion during the quarter, compared to analyst estimates of $14.08 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The firm’s quarterly revenue was up 16.1% on a year-over-year basis. During the same period last year, the company posted $1.24 EPS. Research analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Monday, September 8th. Shareholders of record on Friday, August 8th were paid a dividend of $0.505 per share. This represents a yield of 200.0%. The ex-dividend date of this dividend was Friday, August 8th. AstraZeneca’s dividend payout ratio (DPR) is presently 37.97%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.